Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Gamme d'année
1.
Biol Res ; 57(1): 24, 2024 May 06.
Article de Anglais | MEDLINE | ID: mdl-38711133

RÉSUMÉ

Despite the record speed of developing vaccines and therapeutics against the SARS-CoV-2 virus, it is not a given that such success can be secured in future pandemics. In addition, COVID-19 vaccination and application of therapeutics remain low in developing countries. Rapid and low cost mass production of antiviral IgY antibodies could be an attractive alternative or complementary option for vaccine and therapeutic development. In this article, we rapidly produced SARS-CoV-2 antigens, immunized hens and purified IgY antibodies in 2 months after the SARS-CoV-2 gene sequence became public. We further demonstrated that the IgY antibodies competitively block RBD binding to ACE2, neutralize authentic SARS-CoV-2 virus and effectively protect hamsters from SARS-CoV-2 challenge by preventing weight loss and lung pathology, representing the first comprehensive study with IgY antibodies. The process of mass production can be easily implemented in most developing countries and hence could become a new vital option in our toolbox for combating viral pandemics. This study could stimulate further studies, optimization and potential applications of IgY antibodies as therapeutics and prophylactics for human and animals.


Sujet(s)
Anticorps neutralisants , Anticorps antiviraux , COVID-19 , Poulets , Jaune d'œuf , Immunoglobulines , SARS-CoV-2 , Animaux , SARS-CoV-2/immunologie , Anticorps neutralisants/immunologie , COVID-19/prévention et contrôle , COVID-19/immunologie , Poulets/immunologie , Cricetinae , Immunoglobulines/immunologie , Jaune d'œuf/immunologie , Anticorps antiviraux/immunologie , Femelle , Mesocricetus , Vaccins contre la COVID-19/immunologie
2.
Biol. Res ; 572024.
Article de Anglais | LILACS-Express | LILACS | ID: biblio-1564039

RÉSUMÉ

Despite the record speed of developing vaccines and therapeutics against the SARS-CoV-2 virus, it is not a given that such success can be secured in future pandemics. In addition, COVID-19 vaccination and application of therapeutics remain low in developing countries. Rapid and low cost mass production of antiviral IgY antibodies could be an attractive alternative or complementary option for vaccine and therapeutic development. In this article, we rapidly produced SARS-CoV-2 antigens, immunized hens and purified IgY antibodies in 2 months after the SARS-CoV-2 gene sequence became public. We further demonstrated that the IgY antibodies competitively block RBD binding to ACE2, neutralize authentic SARS-CoV-2 virus and effectively protect hamsters from SARS-CoV-2 challenge by preventing weight loss and lung pathology, representing the first comprehensive study with IgY antibodies. The process of mass production can be easily implemented in most developing countries and hence could become a new vital option in our toolbox for combating viral pandemics. This study could stimulate further studies, optimization and potential applications of IgY antibodies as therapeutics and prophylactics for human and animals.

3.
J Proteomics ; 268: 104702, 2022 09 30.
Article de Anglais | MEDLINE | ID: mdl-35988846

RÉSUMÉ

Apolipoprotein knockout (ApoE-/-) and CD57BL/6J mouse models of angiotensin II (Ang II)-induced abdominal aortic aneurysm (AAA) are commonly used in AAA research. However, the similarities and differences in the molecular mechanisms of AAA in these two genotypes have not been reported. In our study, we analyzed proteomics data from ApoE-/- and CD57BL/6J mouse models of Ang II-induced AAA and control mice by LC-MS/MS. Gene set enrichment analysis (GSEA) of differentially abundance proteins (DAPs) in the ApoE-/- or CD57BL/6J mouse groups was performed in R software, and infiltration of immune cells in groups was assessed. DAP that showed the same trend in abundance in ApoE-/- and CD57BL/6J mice (S-DAP) were identified and subjected to GO enrichment, KEGG pathway, and connectivity map (CMap) analyses. The protein-protein interaction (PPI) network of the S-DAP was drawn, the key S-DAP were identified by MCODE, and the transcription factors (TFs) of crucial S-DAP were predicted by iRegulon in Cytoscape. Male ApoE-/- and CD57BL/6J mouse models of Ang II-induced AAA are commonly used in AAA research, and extracellular matrix organization is associated with AAA in both of these models. However, there are some differences between the mechanisms underlying AAA in these two genotypes, and these differences need to be considered when studying AAA and selecting models. SIGNIFICANCE: Our research provided the first insight into the similarity and differential mechanisms of Ang II infused AAA models using ApoE-/- and CD57BL/6J mice. This study might provide the some advises for the selection of Ang II infused AAA models for further AAA researches.


Sujet(s)
Angiotensine-II , Anévrysme de l'aorte abdominale , Angiotensine-II/effets indésirables , Animaux , Anévrysme de l'aorte abdominale/induit chimiquement , Anévrysme de l'aorte abdominale/génétique , Anévrysme de l'aorte abdominale/métabolisme , Apolipoprotéines E/effets indésirables , Apolipoprotéines E/génétique , Chromatographie en phase liquide , Modèles animaux de maladie humaine , Mâle , Souris , Souris de lignée C57BL , Souris knockout , Protéomique , Spectrométrie de masse en tandem , Facteurs de transcription
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE